Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

20073,643 citationsJournal Article

Authors

Gary R. Hudes · Fox Chase Cancer Center

Michael A. Carducci · Sidney Kimmel Comprehensive Cancer Center

Piotr Tomczak · Centrum Onkologii

Janice Dutcher · Lady of Mercy Medical Center

Robert A. Figlin · University of California, Los Angeles

Anil Kapoor · McMaster University

Elżbieta Starosławska

Abstract

As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Tuberous Sclerosis Complex Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 22, pp. 2271-2281

DOI: 10.1056/nejmoa066838

Field-Weighted Citation Impact: 236.68